Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis

Dedeoglu, Alpaslan, Cormier, Kerry, Payton, Sandra, Tseitlin, Katya A., Kremsky, Jonathan N., Lai, Li, Li, Xiaohua, Moir, Robert D. +5 more·2004·Experimental Gerontology
DOI 10.1016/j.exger.2004.08.016

Cited by (141)

Items 101–141 of 141

  1. Pharmacotherapy of Alzheimer’s Disease: Current State and Future Perspectives
    Jan Korábečný, Filip Zemek, Ondřej Soukup, Katarína Špilovská, Kamil Musílek, Daniel Jun, Eugenie Nepovimová, Kamil Kuča · 2014 · Elsevier eBooks
  2. Characterization of pyridinylimine and pyridinylmethylamine derivatives and their corresponding metal complexes
    Joseph J. Braymer, Nathan M. Merrill, Mi Hee Lim · 2011 · Inorganica Chimica Acta
  3. Targeting misfolding and aggregation of the amyloid-β peptide and mutant p53 protein using multifunctional molecules
    Lauryn Grcic, Grace Leech, Kalvin Kwan, Tim Storr · 2024 · Chemical Communications
  4. Why nutraceuticals do not prevent or treat Alzheimer's disease
    Anna E.O. Fisher, Declan Patrick Naughton · 2005 · Nutrition Journal
  5. Nitrite reductase activity of heme and copper bound Aβ peptides
    Arnab Kumar Nath, Chandradeep Ghosh, Madhuparna Roy, Manas Seal, Somdatta Ghosh Dey · 2019 · Dalton Transactions
  6. Combining conformational sampling and selection to identify the binding mode of zinc-bound amyloid peptides with bifunctional molecules
    Liang Xu, Ke Gao, Chunyu Bao, Xicheng Wang · 2012 · Journal of Computer-Aided Molecular Design
  7. Rethinking IRPs/IRE system in neurodegenerative disorders: looking beyond iron metabolism.
    Zheng-Yang Yao, Lin Fu, F. Jia, Ming-Xia Bi, Q. Jiao, Xi Chen, Xi-Xun Du, Hong Jiang · 2021 · Ageing Research Reviews
  8. 1-(2-Hydroxyethoxy)Methyl-2-Methyl-3-Hydroxyl-4-Pyridinone: ATargeted, Bifunctional Chelating Agent for Potential Uranic Detoxification in the Kidney
    Gang Liu, Ping Men, GERRY H. KENNER · 2011 · Hemoglobin
  9. Targeting Metal Homeostasis as a Therapeutic Strategy for Alzheimer’s Disease
    Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, Vilella, Antonietta, Daini, Eleonora, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, De Benedictis, Chiara A., Cellular Neurobiology and Neuro-Nanotechnology Lab, Department of Biological Sciences, University of Limerick, Limerick, Ireland, Grabrucker, Andreas M., Cellular Neurobiology and Neuro-Nanotechnology Lab, Department of Biological Sciences, University of Limerick, Limerick, Ireland, Bernal Institute, University of Limerick, Limerick, Ireland, Health Research Institute (HRI), University of Limerick, Limerick, Ireland · 2020 · Alzheimer’s Disease: Drug Discovery
  10. Microenvironment-tailored nanoassemblies for the diagnosis and therapy of neurodegenerative diseases
    Liang Ee Low, Qiyue Wang, Ying Chen, Peihua Lin, Shengfei Yang, Linji Gong, Jiyoung Lee, Sangeetaprivya P. Siva, Bey Hing Goh, Fangyuan Li et al. · 2021 · Nanoscale
  11. Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
    Laurent Lecanu, Vassilios Papadopoulos · 2007 · Recent Patents on CNS Drug Discovery
  12. Ligand Design to Target and Modulate Metal–Protein Interactions in Neurodegenerative Diseases
    Michael W. Beck, Amit S. Pithadia, Alaina S. DeToma, Kyle J. Korshavn, Mi Hee Lim · 2014 · Wiley eBooks
  13. Design and Applications of Bifunctional Small Molecules in Biology
    Shelton R. Boyd, Lyra Chang, Wanderson Cabral de Rezende, Idris O. Raji, Prasanna Kandel, Secondra L. Holmes, Damian W. Young · 2020 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
  14. Plasma and CSF Abeta for the longitudinal prediction of Alzheimer's disease dementia and other dementias in people with cognitive decline but no dementia
    Craig William Ritchie, Colin Louis Masters, Sam Mason, Qiao‐Xin Li, Rupert H. McShane · 2011 · Cochrane Database of Systematic Reviews
  15. A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer’s Disease in 5XFAD Mice
    Hadar Segal‐Gavish, Ortal Danino, Yael Barhum, Tali Ben‐Zur, Ella Shai, David Varon, Daniel Offen, Bilha Fischer · 2017 · Journal of Alzheimer s Disease
  16. Sialic Acid Hydroxamate: A Potential Antioxidant and Inhibitor of Metal‐Induced β‐Amyloid Aggregates
    Rohan Yadav, Raghavendra Vasudeva Murthy, Raghavendra V Kikkeri · 2015 · ChemBioChem
  17. Metabolism of copper and possibilities for its regulation
    Peep Palumaa · 2023 · Proceedings of the Estonian Academy of Sciences
  18. Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.
    Willam T Wang, Breeya A Tailor, David S Cohen, Xudong Huang · 2019 · PubMed
  19. The Essentiality of Iron Chelation in Neuroprotection
    Hailin Zheng, Silvia A. Mandel, Tamar Amit, Moussa B. H. Youdim, Orly Weinreb · 2005 · Oxidative stress and disease
  20. Maladies neurodégénératives et stress oxydant
    Elise Lévy · 2020 · theses.fr (ABES)
  21. Progress in the development of new drugs in Alzheimer’s disease
    Antoine Piau, Fati Nourhashémi, Christophe Hein, Céline Caillaud, Bruno J. Vellas · 2010 · The journal of nutrition health & aging
  22. Plasma and Cerebro Spinal Fluid Amyloid Beta 42, 40 and the 42:40 ratio for diagnosis of incipient Dementia in a population with objective cognitive decline.
    Craig William Ritchie, Colin Louis Masters, Sam Mason, Qiao‐Xin Li, Rupert H. McShane · 2010 · Cochrane Database of Systematic Reviews
  23. Metal Chelators as a Potential Therapeutic Agent for Alzheimer’s Disease
    Bhaskar Dewangan, Kunal Kumar, Amit Kumar, Praveen Reddy Bodhe, Sunita Beni, Bichismita Sahu · 2023 · Springer eBooks
  24. Synthesis and bio-activities of bifunctional tetrahydrosalen Cu (II) chelators with potential efficacy in Alzheimer's disease therapy
    Bin Sun, Heyan Jiang · 2024 · Journal of Inorganic Biochemistry
  25. Nouvelles thérapeutiques dans la maladie d’Alzheimer: vers un traitement visant à ralentir la progression de la maladie
    Antoine Piau, Christophe Hein, Fati Nourhashémi, Bruno J. Vellas · 2009 · Les cahiers de l année gérontologique
  26. Deciphering the Significance of Metal Ions in the Pathogenesis of Alzheimer's Disease and Forging Pathways Towards Prospective Therapeutic Strategies
    Junyi Liang, Yueyang Wang, Bin Liu, Xiaohong Dong, Wenhui Cai, Ning Zhang, Hong Zhang · 2023
  27. Metals Involvement in Alzheimer’s Disease Pathogenesis
    Rosanna Squitti, Carlo Salustri · 2011 · InTech eBooks
  28. An Overview of Multifunctional Metal Chelators as Potential Treatments for Neurodegenerative Diseases
    Frank W. Lewis, David Tétard · 2017 · Elsevier eBooks
  29. Drug Development and Alzheimer's Disease
    Julien Delrieu, Antoine Piau, Bruno J. Vellas · 2012 · Wiley eBooks
  30. Development of nano-scale and biomimetic surfaces for biomedical applications
    James E. Henry · 2006 · OakTrust (Texas A&M University Libraries)
  31. PHYSICO-CHEMICAL OPTIMIZATION AND STRUCTURE-ACTIVITY RELATIONSHIP STUDIES OF ALDEHYDE-DERIVED N-ACYLHYDRAZONES: TOWARDS THE IMPROVEMENT OF MODERATE METAL CHELATORS AS A STRATEGY AGAINST METAL-ENHANCED AGGREGOPATHIES
    Daphne Schneider Cukierman · 2021
  32. Interaction entre le zinc(II) et le peptide amyloïde bêta lié à la maladie d'Alzheimer
    Christine Talmard · 2007
  33. Novel regulation of neuronal genes implicated in Alzheimer disease by microRNA
    Justin M. Long · 2013 · IUScholarWorks (Indiana University)
  34. Iron and Monoamine Oxidase in Brain Function and Dysfunction
    Moussa B. H. Youdim, Orly Weinreb, Silvia A. Mandel, Tamar Amit · 2009 · Oxidative stress and disease
  35. Técnicas computacionais aplicadas a uma série de antagonistas do receptor 5-HT>sub<6>/sub< - potencial alvo para a doença de Alzheimer
    Aldineia Pereira da Silva · 2021
  36. Synthesis and Characterization of Second- Generation Iron Pro-chelators
    Lissette R. Perez · 2010 · DukeSpace (Duke University)
  37. Drug development and Alzheimer's disease
    Julien Delrieu, Bruno J. Vellas · 2022 · Wiley eBooks
  38. Plasma and Cerebro Spinal Fluid Amyloid Beta 42, 40 and the 42:40 ratio for diagnosis of incipient Dementia in a population with objective cognitive decline.
    Craig William Ritchie, Colin Louis Masters, Sam Mason, Qiao‐Xin Li, Rupert H. McShane · 2010 · Cochrane Database of Systematic Reviews
  39. Metallic Mysteries: Deciphering Their Contribution to Alzheimer’s Pathogenesis
    SA Kalwaghe, SS Sadar, Pradip Porwal, Shubhangi C. Daswadkar, NS Vyawahare · 2024 · International Journal of Pharmaceutical Sciences and Drug Research
  40. Generation of oxidative stress as an anticancer therapeutic strategy : Investigating the mechanism of action of vitamin C, auranofin and their combination
    Nadine El Banna · 2019
  41. BindingDB Entry 50038080: Multi-target-directed ligands to combat neurodegenerative diseases.
    BindingDB · 2012 · UC San Diego